Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - recombinant omega interferon of feline origin - parenteral liquid/solution/suspension - recombinant omega interferon of feline origin vaccine active 10.0 mu/ml - immunotherapy - cat | dog - adult | cat - queen | cat - tom | kitten - canine parvovirus | feline calicivirus | calicivirus (feline) | fcv | parvovirus

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 2 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - fish oil (unii: xgf7l72m0f) (fish oil - unii:xgf7l72m0f) - omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (pnac). limitations of use: - omegaven is not indicated for the prevention of pnac. it has not been demonstrated that omegaven prevents pnac in parenteral nutrition (pn)-dependent patients [see clinical studies (14)]. - it has not been demonstrated that the clinical outcomes observed in patients treated with omegaven are a result of the omega-6:omega-3 fatty acid ratio of the product [see clinical studies (14)]. use of omegaven is contraindicated in patients with: - known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients [see warnings and precautions (5.2)]. - severe hemorrhagic disorders due to a potential effect on platelet aggregation. - severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentrations greater than 1,000 mg/dl) [see warnings and precautions (5.6)]. risk summary there are no av

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine -

European Union - English - EMA (European Medicines Agency)

virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.

New Zealand - English - Ministry for Primary Industries

virbac new zealand limited - recombinant feline omega interferon - recombinant feline omega interferon 10,000 thou iu/ml - immune stimulant

United States - English - NLM (National Library of Medicine)

tmig, inc. - vitamin d (unii: 9vu1ki44gp) (vitamin d - unii:9vu1ki44gp) - vitamin d 1000 [iu] - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). usage considerations : patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consider